Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)

NCT07218354 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT07218354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)
Lead sponsor
VA Office of Research and Development
Phase
Phase 3
Overall status
Recruiting
Start date
July 28, 2026
Completion date
March 30, 2030
Enrollment
622 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder